Corporate Profile
BioMonde is a private holding company whose principle subsidiaries, Charishealth International SA (pty) Limited, BioMonde Preparations Limited, and Nutrisearch Limited, research, develop, manufacture and make available proprietary nutraceutical products and healthcare services. These products and services are marketed as adjuncts to major drugs, as dietary foods, nutritional health supplements, and healthcare programs, under the BioMonde, Nutrisearch, and CharisHealth labels.
BioMonde’s business has three distinct segments:
research and development segment
- BioMonde is currently focused on the prevention and management of HIV/AIDS, Cancer, HCV, HBV, and Diabetes. BioMonde works closely with medical academia, hospitals, clinics and general practitioners in Europe, USA and Africa to evaluate the safety, efficacy of its proprietary nutraceutical 's as primary and adjunct therapies.
proprietary nutraceutical segment
- BioMonde currently manufactures 25+ proprietary nutraceuticals and active ingredients largely concentrated in the core therapeutic categories: anti-inflammatory; anti-viral; anti-cancer; and anti-diabetic. These categories are common to most chronic illnesses including: HIV/AIDS, HCV, HBV, Cirrhosis, Diabetes, Cancer, Fatty Liver, Alcohol and Drug induced Hepatitis, and Chemotherapy complications. The Heparvit™, ExCell™ and Nutrisearch™ ranges of nutraceuticals are available as special medicinal, nutritional, dietary health and sports supplements.
healthcare segment
- BioMonde developed the Charishealth System™ as a model for establishing and operating healthcare clinics. Charishealth is primarily a non-profit organization, providing centralized logistical support, education, training, management, and medicines to Charishealth affiliated clinics. In South Africa, these clinics are tailored to deliver primary and secondary healthcare services into rural and deprived communities. The key to the success of this healthcare program is the availability of BioMonde adjuncts to HAART (anti-retroviral) therapy, making the therapy more viable, tolerable and effective.
BioMonde has consistently made significant investments in research and development because of our belief that a broad portfolio of products in development is critical to our long-term success. BioMonde expects to continue to invest aggressively in research and development projects in fiscal 2010 and beyond.
To supplement internal efforts in support of its business
strategies, BioMonde continually evaluates business development
opportunities and partnership arrangements that may involve new
technology platforms that it believes will strengthen our product
portfolio and the scope of specialized treatments available via
Charishealth clinics. As BioMonde continues its growth strategy, the
Company expects that business development activities, including
product and company acquisitions will continue to increase.
